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1. Introduction 
Pulmonary arterial smooth muscle cell (PASMC) proliferation in response to hypoxia is 
thought to be a key component of the vascular remodeling that occurs in chronic hypoxic 
pulmonary hypertension. Many pulmonary disorders, including chronic obstructive pul-
monary disease, are associated with chronic hypoxia, and when pulmonary hypertension 
and right heart failure develop due to pulmonary vascular remodeling, patient survival is 
impaired. Hypoxia is one of the factors known to cause secondary pulmonary hypertension 
and pulmonary vascular remodeling [1]. According to a WHO statement in 1996, there were 
approximately 140 million people living at altitudes above 2500m and there are several areas 
of permanent habitation at altitudes in excess of 4000 m. After several weeks of exposure to 
high altitude, lowlanders develop pulmonary hypertension, which is not completely re-
versed by supplemental oxygen [2], suggesting development of vascular remodeling of the 
lung [3]. Secondary pulmonary hypertension is characterized by proliferation of vascular 
smooth muscle cells and pulmonary arterial fibroblasts in small pulmonary vessels [4-6]. 
These results suggest that hypoxic enhancement of PASMC proliferation contributes to the 
progression of hypoxia-associated small pulmonary arterial remodeling and secondary 
pulmonary hypertension. In animals, hypoxia has been shown to cause pulmonary vascular 
wall thickening by inducing PASMC proliferation [7-9]. Most commonly, pulmonary vascu-
lar remodeling is studied in rats or mice exposed to 10% oxygen hypoxia for 2 to 8 weeks 
[9,10]. In the animals exposed to chronic hypoxia, muscular arteries increase the thickness 
and distal extension and migration of PASMC into normally non-muscular arteries can be 
observed (Figure 1). 
In addition, many in vitro studies have also addressed the proliferation of vascular smooth 
muscle cells upon exposure to hypoxia [11,12]. Increased levels of growth factors derived 
from the accumulation of hypoxia-inducible factor 1α (HIF-1α) are thought to regulate  
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Figure 1. Proliferating cell nuclear antigen (PCNA) staining of small pulmonary arteries from mice 
exposed to chronic hypoxia (10% oxygen) for 8 weeks. PCNA positive cells were found in the smooth 
muscle layer of small pulmonary arteries (right picture) compared with normoxic control (left picture). 
PASMC proliferation under hypoxic conditions, since a partial HIF-1α deficiency decreases 
muscularization of pulmonary arterioles in animals exposed to chronic hypoxia [7]. However, 
it is unclear whether hypoxia is a direct mitogen or indirect mitogen induced by the 
mediators from endothelial cells or fibroblasts, because some investigators have shown that 
hypoxia is not a direct stimulus of PASMC proliferation [13,14]. This discrepancy may be 
explained by the severity of hypoxia. The investigators who have found PASMC proliferation 
by hypoxic exposure usually used the moderate hypoxia (1 – 5% oxygen) [1,11,12,15,16]. 
Although HIF-1α regulates various transcriptional genes for angiogenic factors, severe hy-
poxia and iron depletion induce cell growth arrest. In contrast to severe hypoxia, moderate 
hypoxia can also enhances the proliferation of airway-smooth muscle cells, lung fibroblasts 
and mesangial cells [17,18]. Proliferation of PASMCs, which causes pulmonary vascular 
remodeling, requires re-entry of the cells into the cell cycle. We confirmed that the cultured 
PASMC cell cycle progresses more quickly in hypoxia and that severe hypoxia or iron de-
pletion using an iron chelator, which mimics anoxia, caused inhibition of cell cycle progress 
compared to the normoxic conditions (Figure 2). 
 
Figure 2. Cell cycle analysis of human pulmonary arterial smooth muscle cells (HPASMC) cultured in 
various concentration of oxygen (0.1%, 2%, 21%) or 100 μM of iron chelator, desferroxamine (DFX) 
using flow cytometric analyses with propidium iodide staining. S+M phases are increased in moderate 
hypoxia (2% oxygen) compared to the normoxic condition. Severe hypoxia (0.1% oxygen) and iron 
chelator decreased the S+M phases in cultured HPASMCs. 
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2. Cell cycle regulation of hypoxic PASMC proliferation 
Under normal physiological conditions, the majority of the pulmonary vascular cells are in a 
quiescent state. The most important molecular event necessary for progression of the cell 
cycle is phosphorylation of the retinoblastoma protein by cyclin-dependent kinase (CDK)-
cyclin complexes. Cell cycle progression requires the coordinated interaction of CDK and its 
regulatory subunits, the cyclins, to drive cells through G1 into S phase to ultimately result in 
cell division. Cyclin–CDK complexes activate transcription factors important in cell cycle 
progression. The cyclin–CDK complexes include cyclin D–CDK4/ CDK6 and cyclin E–CDK2 
which inactivate retinoblastoma, an antitumor and antiproliferative protein which limits 
E2F-mediated gene transcription [19]. CDK inhibitors are proteins that bind cyclin–CDK 
complexes, inhibit hyperphosphorylation of retinoblastoma, cause G1 arrest, and suppress 
cell proliferation [20]. CDK activity can be inhibited by CDK inhibitors, which arrest the cell 
cycle at each corresponding phase and inhibit cell proliferation. Two families of CDK inhibi-
tors have been shown to regulate vascular smooth muscle cell proliferation, p21 and p27. 
The loss of CDK inhibitors has been implicated in tumor development [21,22], and is closely 
related with the state of the tumor suppressor p53 [23,24]. 
2.1. Role of tumor suppressor p53 and CDK inhibitor p21 
The endogenous CDK inhibitor p21 plays an important role in PASMC proliferation via 
induction of the tumor suppressor p53 [23,25], and has been identified as a key regulator of 
the cell cycle in cells exposed to hypoxia and oxidative stress [26-28]. In tumors expressing 
wild-type p53, apoptosis occurs in hypoxic regions, whereas tumors expressing mutant p53 
exhibit lower levels of apoptosis in hypoxic regions [29]. p53-/- mouse embryo fibroblasts 
are more resistant to hypoxia-induced apoptosis, and have selective growth advantages 
compared to wild-type p53 cells [30]. In addition, hypoxic p53 accumulation has been linked 
to the hypoxia-inducible factor-1α (HIF-1α), which is known as a central transcriptional 
factor operating during hypoxia toward angiogenesis [31,32]. We recently reported that 
hypoxic p53 accumulation has been linked to the hypoxia inducible factor-1α (HIF-1α) [9]. 
These results support the view that the p53 protein opposes cell proliferation under hypox-
ia, and p53 plays a critical role as a modulator of hypoxia-induced small pulmonary arterial 
remodeling. Decreased expression of p21 and increased expression of HIF-1α via suppres-
sion of p53 protein may mitigate hypoxic pulmonary arterial remodeling and PASMC pro-
liferation. Recently, several groups identified microRNAs (miRNAs) regulated by p53 
[33,34]. miRNAs are non-coding RNA molecules which modulate gene expression by bind-
ing to complementary sequences in the coding - or the 3`-untranslated region of target 
mRNAs. miRNAs can regulate cell proliferation, differentiation and apoptosis [35,36]. The 
miR34a has been shown to be the most significant miRNA induced by p53, which is closely 
related to induction of apoptosis and cell cycle arrest in cancer cells [37]. We have shown 
that this miRNA is also associated with HIF-1α expression both in animal and human lung 
tissues [9,38,39]. 
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p21 has been shown to regulate cell cycle progression through both p53-dependent and -
independent pathways [24,25,40]. However, it is known that nitric oxide (NO) donors sup-
press proliferation of cultured PASMC via the expression of p53 and p21 [23]. NO is synthe-
sized from L-arginine via nitric oxide synthase (NOS), and endothelial NOS plays an im-
portant regulatory role in hypertrophic and hyperplastic growth of PASMC in vivo and in 
vitro. Several studies have suggested that NO derived from endothelial NOS has a protective 
effect toward arterial smooth muscle cell proliferation [41].[42]. It is possible that the anti-
proliferative effect of NO derived from pulmonary arterial endothelial cells is depend on the 
status of p53 in PASMC. 
In our recent data from p53 knockout mice, chronic hypoxia increased p21 expression and 
induced medial wall thickening of small pulmonary arteries in wild type mice, and the dele-
tion of the p53 gene prevented the hypoxic induction of p21 expression [9]. These results 
indicate that under hypoxic conditions, induction of the p53-p21 signaling pathway serves 
as a negative feed-back to prevent excessive vascular cell proliferation and vascular remod-
eling. Using cultured PASMCs, we confirmed that the anti-proliferative NO pathway was 
intact in the hypoxic condition and the protein expression of p21 was associated with 
HPASMC proliferation (Figure 3). 
 
Figure 3. Western blot analysis of p21 and p53 (left photographs) and BrdU incorporations in cultured 
PASMC exposed hypoxia (2% oxygen) and NO donors (SNAP and DETANO) (right graph). Moderate 
hypoxia decreased p21 and the NO donors increased the both p21 and p53 protein expressions. The NO 
donors suppressed DNA amplification in cultured PASMCs during hypoxia. 
2.2. CDK inhibitor p27 
The suppressive effect of hypoxia on p27 expression has been demonstrated in mice with 
pulmonary hypertension induced by hypoxia [8]. However, the expression of p27, which 
blocks the cell cycle at the G0/1 phase, is regulated by several mechanisms including tran-
scription, protein degradation and translation [43-45]. We reported that hypoxia-induced 
down-regulation of p27 was not mediated by hypoxia per se, but rather by mitogenic factors 
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including PDGF and hypoxia enhanced p27 protein degradation. The moderate hypoxia 
enhanced the proliferation of serum-stimulated PASMC in accordance with promoted p27 
protein degradation, probably via the induction of growth factors [12]. The prostacyclin 
analogue suppressed PASMC proliferation under both hypoxic and normoxic conditions by 
blocking p27 mRNA degradation through an increase in intracellular cAMP. Hypoxia may 
activate HIF-1α regulated growth factors and cell growth signaling such as mitogen activat-
ed protein kinase (MAPK). We also found that hypoxic exposure and p53 regulate MAPK 
activation in cultured PASMCs (Figure 4). To clarify the effect of p53 on the activation of 
MAPK in hypoxic PASMC proliferation, we performed gene silencing of p53 to the cultured 
PASMC. The gene silencing of p53 suppressed MAPK activation, which indicates hypoxic 
activation of MAPK and p53 are also associated with the degradation of p27 and hypoxic 
PASMC proliferation.  
 
Figure 4. Left figure shows protein expressions of phosphorylated ERK1/2 in cultured PASMC exposed 
hypoxia (2 - 10% oxygen). Right figure shows effect of p53 gene silencing on ERK1/2 phosphorylation in 
cultured PASMC exposed to hypoxia (2% oxygen). Hypoxic exposure induced MAPK activation, and 
the p53 protein expression are suppressing the MAPK activation. 
Previous findings have suggested that p27 mRNA stability is controlled by interactions 
between MAPK [46] and Rho-dependent translation[47]. Further, cAMP induces cell relaxa-
tion through Rho GTPase activation [48,49], which might be an important target of hypoxic 
pulmonary vascular remodeling [50,51]. These reports imply that the Rho and MAPK inter-
action contributes to p27 mRNA stability during exposure to agents that elevate cAMP and 
hypoxia. These interactions may be also possible in smooth muscle cells. The Rho inhibitor 
Y-27632 inhibited human aortic smooth muscle proliferation in response to platelet derived 
growth factor and markedly suppressed neointima formation associated with decreased 
expression of p27 in rat carotid artery [52]. Regarding the effect of Rho on the expression of 
p27 in PASMC, we simply measure the p27 protein expression using Rho inhibitor in cul-
tured PASMC and found that the p27 protein expression was increased by Y-27632 (Figure 
5).  
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Figure 5. p27 protein expression in cultured PASMC exposed to hypoxia with 10 μM of Rho inhibitor 
Y-27632 (left figure) and BrdU incorporations in cultured PASMC exposed to hypoxia with or without 
Y-27632 (right graph). The p27 protein expression was increased by the treatment of Rho inhibitor both 
in the normoxic and hypoxic conditions with association of the cell proliferation. 
3. Conclusion 
It is well accepted that hypoxia is a cause of pulmonary vascular remodeling and PASMC 
proliferation. In the aggregate, research conducted by us and others suggests that decreased 
oxygen levels affect PASMC proliferation. Decreased expression of p27 and signal transduc-
tion via p53 and p21 play critical roles in the fine-tuning of hypoxic PASMC proliferation. In 
vitro studies have demonstrated that hypoxia has direct mitogenic effect on cultured 
PASMC by increased production of growth factors and decreased expression of CDK inhibi-
tors. The cell cycle regulation by p53 may be closely related with the severity of hypoxia and 
HIF-1α status (Figure 6). 
However, the hypoxia induced remodeling of the pulmonary circulation including PASMC 
proliferation is a highly complex process, which may have numerous interactions between 
the vascular cells, especially between endothelial cells and lung fibroblasts. Because of that, 
it is difficult to explain the in vivo pulmonary vascular remodeling using single cell culture 
experiments. For example, hypoxic endothelial cells and adventitial fibroblasts around 
PASMC may also be able to release mitogenic factors for PASMC proliferation, and damage 
of vascular endothelial cells by hypoxia can lead the decrease of anti-proliferative mediator 
production resulting PASMC proliferation. In addition, hypoxic proliferation of lung fibro-
blasts can secrete matrix proteins, which may play an important role for the proliferation of 
PASMC [53]. Further studies are necessary to characterize the role of cell cycle regulations 
on the hypoxic vascular cell proliferation, and to clarify the interactions between PASMC, 
pulmonary vascular endothelial cells and fibroblasts. We believe that a better understanding 
of the genetic and cellular mechanisms of hypoxic pulmonary remodeling will lead to im-
proved modes of therapy for hypoxia-associated changes in lung tissue structure and aid in 
the remodeling of pulmonary hypertension. 
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Figure 6. Schematic depicting molecular interactions in the hypoxic PASMC proliferation: Hypoxic 
exposure increases HIF-1α and p53 protein expression. Up-regulated p53 induces p21 expression and 
the p21 inhibit G1/0 transition via inhibition of cyclin/CDK complex. In contrast, HIF-1α activation 
causes up-regulation of growth factors that reduce the expression of p27. Reduced expression of p27 
and increased HIF-1α transactivation induces cyclin/CDK complex, which causes progress of cell cycle 
of pulmonary smooth muscle cell. 
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